Nippon Kayaku licenses Japanese ozarelix rights

13 August 2006

Spectrum Pharmaceuticals says that AEterna Zentaris, the licensor of its fourth-generation luteinizing hormone-releasing hormone antagonist, ozarelix, has entered a licensing agreement with Japan's Nippon Kayaku. Under the terms of the deal, Kayaku has exclusive rights to develop and market the agent for all potential oncological indications in Japan, and in return will pay AEterna upfront fees, royalties and milestones, of which Spectrum is entitled 50%.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight